Secure? Terry, you really need to stop posting. You are not even amusing any longer. Longs laugh at you all day as we approach new highs and another major step in Insmeds development. You bring shame to shorts. They really do not like you. You make them all look very fooloish.
- It's the first time I saw a more specific number for Kodak's emerging functional printing business. It struck me how small their expected "addressed market" is for functional printing.
Graphic Communication: $13B
Functional Printing: $2B
If you allow me to take a seat-of-the-pants guess of 20% market share for Kodak and its partners, incl. UNXL, that would imply $400 m of revenue from that market. Assume that half of it goes to Kodak and half to its partners, and you end with revenue of $200 m for Kodak .... not bad, but that number wouldn't rock Kodak's boat, esp. in 2014. (If I were an UNXL investor, this addressed market size would scare the hell out of me.)
- Kodak now bundles/obfuscates inkjet with traditional print (much of it is plating). Too bad, they don't tell us how big the addressed market for their commercial inkjet printers / Prosper XL's is.
- Good thing they still acknowledge to be on track with their EBITDA prognostications for 2013. I agree this should be doable. But I certainly can't trace Perez's expected revenues/EBITDA for 2014 into the real world yet, given the expected decline of their high margin consumer ink sales in 2014. With the muted addressed market size for functional printing, Perez's numbers sound like wishful thinking again. No surprise here. Maybe, they plan on acquiring UNXL _if_ Uniboss is a viable product, which would boost revenues and EBITDA but likely dilute the new shareholders ...
EBITDA : On track to deliver $167 million in 2013 and $494 million in 2017
Capital Structure: Approximately $500 million in equity; Debt of $695 million; and Cash of more than $800 million at emergence.
Dear Mr xxxxxxx:
Thank you for contacting me with your thoughts about Fannie Mae and Freddie Mac. As you indicate, we have seen recent improvement in Fannie and Freddie's operations, however, each entity still owes taxpayers repayment of bailout funds and will continue to pay the Treasury dividends on any future earnings.
You will be pleased to know that both the Senate and House are reviewing different proposals to take Fannie and Freddie out of conservatorship and reform the nation's housing finance system. With President Obama's recent remarks indicating his willingness to work with Congress on this issue, I expect that we will see some more activity on Fannie and Freddie in the coming months.
Again, thank you for sharing your concerns.
Member of Congress
Sentiment: Strong Buy
Keepshorting is a delusional wingnut. He is living proof there are no rules in chat forums.
I agree nvax will be sold but not till mid 2014 if the OS keeps increasing the lower the sp will be with a buyout - greed - they want a high sp now with a 185,000 sh float its all about market cap $12 to $13
is my guess
Will it be bankruptcy, suicide, or will macclellan lose everything he owns in the class action trail???
Sentiment: Strong Sell
Looks like all shorts can only comment by giving a thumbs down. LOL.
They can't argue that Misek has made a fool of himself with his ever changing target prices that are now 20% below where the stock is currently trading at.
Sentiment: Strong Buy
Yeah, but those 2 had wrong conclusions, not wrong facts. Dare i stick up for Ineedaclue?
At leat that guy makes 3 coherent sentences before he goes off on a riff that could chalange jimmi henricks. I mean look what hendricks did with the star spangled banner!
Ineedastock is Hendricks man!
With a lot more coke and no guitar.
I think they(shorts) are looking at the historic action after earnings to save them. My question is , why take the chance, since the upside to being short into the Q3 call is very limited and the downside to staying short into that day is very bad for a short player. I don't think history will be replayed this Q and a rise in share price is more likely. There has to be a better short play than this, with a more predictable outcome. It can play out very nicely though for us and the 50% rise in share price the next day. While they cover.
Sentiment: Strong Buy
If he has something worth while to say, he definitely has my cell number. I leave it at every CC.
Until that time, I'm DONE with excuses like "gee, this is really hard and stuff ya know...."
Try this overview. Seek out a large metro city and explore the EPA/DEP weekly reports the powerhouses submit, we study all areas of USA with paid reports. Calculate the tons of air volume vs energy input. Gas molecule breaks into diff chem of destruction eff. apply the actual producing volume trend of NG, with the weather, volume trend and many more factors! Now RIG count, is only a bases, there are many other factors that provide NG to the pipelines. Rigs are not the only provider. Did you folks know that a simple landfill can produce more NG than a RIG.
Sold this during the last spike to $9 in July. Suprisingly this is still dancing at $8. I bought alu and have since double my money. However I intend to come back when alu run to $4 shortly. Please stay below $9 for another week.
HOUSTON (KTRK) -- Finally, Houston humans are getting a shot at a cutting edge treatment that Houston Zoo animals have been getting -- stem cells for injured knees. And the stem cells come from your belly fat!
"When I was playing basketball, I made a pivot stop and it just tore," Jesse Flores said.
And it keeps happening. So Flores just had his sixth surgery on his right knee and will soon have a second surgery on his left knee.
"I want the stem cells to try and regrow the cartilage so this doesn't keep on happening," Flores said.
He's talking about stem cells taken from his own belly fat. It's the same procedure that InGeneron, a Houston company, performed on the zoo's black leopard to help with arthritic joints. Now they are testing it to see if fat cells from your belly and help the cartilage in an injured human knee.
"Theoretically, we should be able to get them back to where they were before the injury, which is their normal knee status," orthopedic surgeon Dr. Robert Burke said.
Fifty people will be in the stem cell study. Half will have surgery, plus stem cells. Half will just have the surgery. Then they'll compare them in six months and 12 months.
Sentiment: Strong Buy